CD19 and cancer: In relation to this, 28 samples from patients with r/r DLBCL who received Axicabtagene ciloleucel and 50 newly diagnosed cases of DLBCL from the Pan-Cancer Analysis of Whole Genomes (PCAWG) were analyzed to understand the genomic drivers of resistance to CD19-CAR T cell therapy [61].